Showing 801 - 820 results of 47,311 for search '(( 5 ((fold decrease) OR (mean decrease)) ) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 0.83s Refine Results
  1. 801
  2. 802
  3. 803
  4. 804

    The primers related to FAM50A. by Longhai Li (4052044)

    Published 2025
    “…Knockdown of FAM50A decreased cell proliferation ability, the proportion of EdU positive cells, and the number of CRC cell colonies, whereas overexpressing FAM50A promoted proliferative phenotypes. …”
  5. 805
  6. 806
  7. 807

    Inhibition of GLS1 decreases the proportion of CCR6 and CXCR3 expressing CD4<sup>+</sup> T cells. by Zeynep Sener (3146064)

    Published 2016
    “…BPTES and 968 significantly decrease the proportion of CCR6 expressing cells under normoxia both at day 3 and 5, whereas 968 but not BPTES decrease the proportion of CCR6 expressing cells under hypoxia both at day 3 and 5. …”
  8. 808
  9. 809

    Fig 7 - by C. Vijay Reena Durai (14498259)

    Published 2023
    Subjects:
  10. 810
  11. 811
  12. 812
  13. 813

    Fig 1 - by C. Vijay Reena Durai (14498259)

    Published 2023
    Subjects:
  14. 814
  15. 815
  16. 816
  17. 817
  18. 818
  19. 819

    U87MG glioma cells transduced with gal-3 shRNA demonstrate decreased tumor size and growth. by Rafael Yamashita Ikemori (698128)

    Published 2014
    “…The inoculation of U87MG gal-3 shRNA cells in the flank of nuce mice (n = 5) demonstrated a decrease in tumor size and growth compared to the U87MG scramble shRNA (n = 6). …”
  20. 820

    Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis-2 by Mrigank Srivastava (94935)

    Published 2011
    “…(F) Gelatin zymography employing concentrated BAL fluid protein from mock- or bleomycin-treated wild-type mice and cath K tg mice. Data are shown as mean ± SD of n = 3 determinations. (B-F), data represent at least n = 3–5 independent analyses. * indicates < 0.05 versus bleomycin-treated wild-type mice at day 14 post-treatment.…”